<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37095536</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2049-9957</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>24</Day></PubDate></JournalIssue><Title>Infectious diseases of poverty</Title><ISOAbbreviation>Infect Dis Poverty</ISOAbbreviation></Journal><ArticleTitle>Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>43</StartPage><MedlinePgn>43</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">43</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40249-023-01086-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Coronavirus disease 2019 (COVID-19) can involve persistence, sequelae, and other clinical complications that last weeks to months to evolve into long COVID-19. Exploratory studies have suggested that interleukin-6 (IL-6) is related to COVID-19; however, the&#xa0;correlation between IL-6 and long COVID-19 is unknown. We designed a systematic review and meta-analysis to assess the relationship between IL-6 levels and long COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Databases were systematically searched for articles with data on long COVID-19 and IL-6 levels published before September 2022. A total of 22 published studies were eligible for inclusion following the PRISMA guidelines. Analysis of data was undertaken by using Cochran's Q test and the Higgins I-squared (I<sup>2</sup>) statistic for heterogeneity. Random-effect meta-analyses were conducted to pool the IL-6 levels of long COVID-19 patients and to compare the differences in IL-6 levels among the long COVID-19, healthy, non-postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (non-PASC), and acute COVID-19 populations. The funnel plot and Egger's test were used to assess potential publication bias. Sensitivity analysis was used to test the stability of the results.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">An increase in IL-6 levels was observed after SARS-CoV-2 infection. The pooled estimate of IL-6 revealed a mean value of 20.92&#xa0;pg/ml (95% CI&#x2009;=&#x2009;9.30-32.54&#xa0;pg/ml, I<sup>2</sup>&#x2009;=&#x2009;100%, P&#x2009;&lt;&#x2009;0.01) for long COVID-19 patients. The forest plot showed high levels of IL-6 for long COVID-19 compared with healthy controls (mean difference&#x2009;=&#x2009;9.75&#xa0;pg/ml, 95% CI&#x2009;=&#x2009;5.75-13.75&#xa0;pg/ml, I<sup>2</sup>&#x2009;=&#x2009;100%, P&#x2009;&lt;&#x2009;0.00001) and PASC category (mean difference&#x2009;=&#x2009;3.32&#xa0;pg/ml, 95% CI&#x2009;=&#x2009;0.22-6.42&#xa0;pg/ml, I<sup>2</sup>&#x2009;=&#x2009;88%, P&#x2009;=&#x2009;0.04). The symmetry of the funnel plots was not obvious, and Egger's test showed that there was no significant small study effect in all groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study showed that increased IL-6 correlates with long COVID-19. Such an informative revelation suggests IL-6 as a basic determinant to predict long COVID-19 or at least inform on the "early stage" of long COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Jing-Xian</ForeName><Initials>JX</Initials><AffiliationInfo><Affiliation>School of Global Health, Chinese Centre for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agbana</LastName><ForeName>Yannick Luther</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Pan African University Life and Earth Sciences Institute (PAULESI), University of Ibadan, Ibadan, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Zhi-Shan</ForeName><Initials>ZS</Initials><AffiliationInfo><Affiliation>School of Global Health, Chinese Centre for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fei</LastName><ForeName>Si-Wei</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>School of Global Health, Chinese Centre for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Han-Qing</ForeName><Initials>HQ</Initials><AffiliationInfo><Affiliation>School of Global Health, Chinese Centre for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiao-Nong</ForeName><Initials>XN</Initials><AffiliationInfo><Affiliation>School of Global Health, Chinese Centre for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Parasitic Diseases at Chinese Centre for Disease Control and Prevention (Chinese Centre for Tropical Diseases Research), National Health Commission of the People's Republic of China (NHC) Key Laboratory of Parasite and Vector Biology, World Health Organization (WHO) Collaborating Centre for Tropical Diseases, National Centre for International Research On Tropical Diseases of the Chinese Ministry of Science and Technology, Shanghai, 200025, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jun-Hu</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>National Institute of Parasitic Diseases at Chinese Centre for Disease Control and Prevention (Chinese Centre for Tropical Diseases Research), National Health Commission of the People's Republic of China (NHC) Key Laboratory of Parasite and Vector Biology, World Health Organization (WHO) Collaborating Centre for Tropical Diseases, National Centre for International Research On Tropical Diseases of the Chinese Ministry of Science and Technology, Shanghai, 200025, People's Republic of China. chenjh@nipd.chinacdc.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kassegne</LastName><ForeName>Kokouvi</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7067-177X</Identifier><AffiliationInfo><Affiliation>School of Global Health, Chinese Centre for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China. kassegnek@sjtu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Infect Dis Poverty</MedlineTA><NlmUniqueID>101606645</NlmUniqueID><ISSNLinking>2049-9957</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Immune mediator</Keyword><Keyword MajorTopicYN="N">Interleukin-6</Keyword><Keyword MajorTopicYN="N">Long COVID-19</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Xiao-Nong Zhou is the Editor-in-Chief of <i>Infectious Diseases of Poverty</i>. He was not involved in the peer review or handling of the manuscript. The authors have no other competing interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>25</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>24</Day><Hour>11</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37095536</ArticleId><ArticleId IdType="pmc">PMC10123579</ArticleId><ArticleId IdType="doi">10.1186/s40249-023-01086-z</ArticleId><ArticleId IdType="pii">10.1186/s40249-023-01086-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lam TT, Jia N, Zhang YW, Shum MH, Jiang JF, Zhu HC, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature. 2020;583(7815):282&#x2013;285. doi: 10.1038/s41586-020-2169-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2169-0</ArticleId><ArticleId IdType="pubmed">32218527</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao HQ, Fei SW, Yin JX, Li Q, Jiang TG, Guo ZY, et al. Assessment of performance for a key indicator of One Health: evidence based on One Health index for zoonoses in Sub-Saharan Africa. Infect Dis Poverty. 2022;11(1):109. doi: 10.1186/s40249-022-01020-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-022-01020-9</ArticleId><ArticleId IdType="pmc">PMC9588233</ArticleId><ArticleId IdType="pubmed">36273213</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE guideline [NG191]. in COVID-19 rapid guideline: managing the long-term effects of COVID-19. British: National Institute for Health and Care Excellence (NICE); 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251&#x2013;2252. doi: 10.1001/jama.2020.22717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22717</ArticleId><ArticleId IdType="pubmed">33206133</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M, Felten R, Gallais F, Nazon C, Chatelus E, Pijnenburg L, et al. Refining &#x201c;Long-COVID&#x201d; by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-CoV-2 infection. Infect Dis Ther. 2021;10(3):1747&#x2013;1763. doi: 10.1007/s40121-021-00484-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-021-00484-w</ArticleId><ArticleId IdType="pmc">PMC8270770</ArticleId><ArticleId IdType="pubmed">34245450</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Coronavirus Disease (COVID-19). Dashboard. https://covid19.who.int/, Accessed 30 Aug 2022.</Citation></Reference><Reference><Citation>Mahase E. Covid-19: What do we know about "long covid"? BMJ. 2020;370:m2815. doi: 10.1136/bmj.m2815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m2815</ArticleId><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenko E, Badimon L, Bugiardini R, Claeys MJ, De Luca G, De Wit C, et al. Cardiovascular disease and COVID-19: A consensus paper from the ESC Working Group on Coronary Pathophysiology &amp; Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA) Cardiovasc Res. 2021;117(14):2705&#x2013;2729. doi: 10.1093/cvr/cvab298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvab298</ArticleId><ArticleId IdType="pmc">PMC8500019</ArticleId><ArticleId IdType="pubmed">34528075</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021;93(2):1013&#x2013;1022. doi: 10.1002/jmv.26368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420&#x2013;422. doi: 10.1016/S2213-2600(20)30076-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30076-X</ArticleId><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, et al. The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. 2022;3(6):100663. doi: 10.1016/j.xcrm.2022.100663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz MAF, Neves P, Lima SS, Lopes JDC, Torres M, Vallinoto I, et al. Cytokine profiles associated with acute COVID-19 and long COVID-19 syndrome. Front Cell Infect Microbiol. 2022;12:922422. doi: 10.3389/fcimb.2022.922422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. doi: 10.1101/cshperspect.a016295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a016295</ArticleId><ArticleId IdType="pmc">PMC4176007</ArticleId><ArticleId IdType="pubmed">25190079</ArticleId></ArticleIdList></Reference><Reference><Citation>Fain JN. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Inflamm. 2010;2010:513948. doi: 10.1155/2010/513948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2010/513948</ArticleId><ArticleId IdType="pmc">PMC2874930</ArticleId><ArticleId IdType="pubmed">20508843</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi L, Li Y, Stehno-Bittel L, Gao J, Morrison DC, Stechschulte DJ, et al. Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-alpha. J Interferon Cytokine Res. 2001;21(4):231&#x2013;240. doi: 10.1089/107999001750169871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/107999001750169871</ArticleId><ArticleId IdType="pubmed">11359654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappelmann N, Dantzer R, Khandaker GM. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology. 2021;131:78. doi: 10.1016/j.psyneuen.2021.105295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2021.105295</ArticleId><ArticleId IdType="pmc">PMC8172271</ArticleId><ArticleId IdType="pubmed">34119855</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuwa HA, Shaw TN, Knight SB, Wemyss K, McClure FA, Pearmain L, et al. Alterations in T and B cell function persist in convalescent COVID-19 patients. Med (N Y). 2021;2(6):720&#x2013;735.e724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8011689</ArticleId><ArticleId IdType="pubmed">33821250</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Agbana YL, Abi ME, Ni Y, Xiong G, Chen J, Yun F, et al. LINC00511 as a prognostic biomarker for human cancers: a systematic review and meta-analysis. BMC Cancer. 2020;20(1):682. doi: 10.1186/s12885-020-07188-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-020-07188-3</ArticleId><ArticleId IdType="pmc">PMC7376647</ArticleId><ArticleId IdType="pubmed">32698787</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z, Gu Q, Dai Y, Zou H, Agins B, Chen Q, et al. Increasing awareness of HIV pre-exposure prophylaxis (PrEP) and willingness to use HIV PrEP among men who have sex with men: a systematic review and meta-analysis of global data. J Int AIDS Soc. 2022;25(3):e25883. doi: 10.1002/jia2.25883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jia2.25883</ArticleId><ArticleId IdType="pmc">PMC8901150</ArticleId><ArticleId IdType="pubmed">35255193</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Yomogida K, Zhu S, Rubino F, Figueroa W, Balanji N, Holman E. Post-Acute Sequelae of SARS-CoV-2 Infection Among Adults Aged &#x2265;18 Years - Long Beach, California, April 1-December 10, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(37):1274&#x2013;1277. doi: 10.15585/mmwr.mm7037a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7037a2</ArticleId><ArticleId IdType="pmc">PMC8445372</ArticleId><ArticleId IdType="pubmed">34529639</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603&#x2013;605. doi: 10.1007/s10654-010-9491-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-010-9491-z</ArticleId><ArticleId IdType="pubmed">20652370</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. doi: 10.1186/1471-2288-14-135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-135</ArticleId><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>Said EA, Al-Reesi I, Al-Shizawi N, Jaju S, Al-Balushi MS, Koh CY, et al. Defining IL-6 levels in healthy individuals: A meta-analysis. J Med Virol. 2021;93(6):3915&#x2013;3924. doi: 10.1002/jmv.26654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26654</ArticleId><ArticleId IdType="pubmed">33155686</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich JO, Adhikari NK, Beyene J. The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study. BMC Med Res Methodol. 2008;8:32. doi: 10.1186/1471-2288-8-32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-8-32</ArticleId><ArticleId IdType="pmc">PMC2430201</ArticleId><ArticleId IdType="pubmed">18492289</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich JO, Adhikari NK, Beyene J. Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods. J Clin Epidemiol. 2011;64(5):556&#x2013;564. doi: 10.1016/j.jclinepi.2010.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.09.016</ArticleId><ArticleId IdType="pubmed">21447428</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian G, Mahdi A. Sensitivity analysis methods in the biomedical sciences. Math Biosci. 2020;323:108306. doi: 10.1016/j.mbs.2020.108306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mbs.2020.108306</ArticleId><ArticleId IdType="pubmed">31953192</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan K, Dedeepiya VD, Suryaprakash V, Rao KS, Ikewaki N, Sonoda T, et al. Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3&#x2013;1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study. Biomed Pharmacother. 2022;145:9. doi: 10.1016/j.biopha.2021.112243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.112243</ArticleId><ArticleId IdType="pmc">PMC8463314</ArticleId><ArticleId IdType="pubmed">34840031</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Pache F, K&#xf6;rtvelyessy P, Jel&#x10d;i&#x107; I, Stettner M, Franciotta D, et al. Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. J Neuroinflam. 2022;19(1):9. doi: 10.1186/s12974-021-02339-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02339-0</ArticleId><ArticleId IdType="pmc">PMC8771621</ArticleId><ArticleId IdType="pubmed">35057809</ArticleId></ArticleIdList></Reference><Reference><Citation>Albanese M, Marrone G, Paolino A, Di Lauro M, Di Daniele F, Chiaramonte C, et al. Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case-Control Study. Pharmaceuticals. 2022;15(2):452. doi: 10.3390/ph15020253.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15020253</ArticleId><ArticleId IdType="pmc">PMC8878249</ArticleId><ArticleId IdType="pubmed">35215365</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Guevara-Coto J, Yogendra R, Francisco EB, Long E, Pise A, et al. Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning. Front Immunol. 2021;12:700782. doi: 10.3389/fimmu.2021.700782.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.700782</ArticleId><ArticleId IdType="pmc">PMC8273732</ArticleId><ArticleId IdType="pubmed">34262570</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha SI, Samaan SF, Ibrahim RA, El-Sehsah EM, Youssef MK. Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity? Eur Cytokine Netw. 2021;32(4):83&#x2013;88. doi: 10.1684/ecn.2021.0471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1684/ecn.2021.0471</ArticleId><ArticleId IdType="pmc">PMC8831681</ArticleId><ArticleId IdType="pubmed">35118946</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros C, Freire RS, Frota E, Rezende Santos AG, Farias MEL, Rodrigues MGA, et al. Short-Course of Methylprednisolone Improves Respiratory Functional Parameters After 120 Days in Hospitalized COVID-19 Patients (Metcovid Trial): A Randomized Clinical Trial. Front Med (Lausanne). 2021;8:758405. doi: 10.3389/fmed.2021.758405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.758405</ArticleId><ArticleId IdType="pmc">PMC8669506</ArticleId><ArticleId IdType="pubmed">34917633</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodr&#xed;guez Y, Zapata E, Ram&#xed;rez-Santana C, et al. Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome. J Infect Dis. 2022;225(12):2155&#x2013;2162. doi: 10.1093/infdis/jiac017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac017</ArticleId><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Zurbuchen Y, Taeschler P, Ballouz T, Menges D, Hasler S, et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. 2022;13(1):446. doi: 10.1038/s41467-021-27797-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Colarusso C, Maglio A, Terlizzi M, Vitale C, Molino A, Pinto A, et al. Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-&#x3b2; but Higher Levels of IL-1&#x3b1; and TGF-&#x3b2;. Biomedicines. 2021;9(12):8. doi: 10.3390/biomedicines9121931.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9121931</ArticleId><ArticleId IdType="pmc">PMC8698335</ArticleId><ArticleId IdType="pubmed">34944747</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugani P, Mehta A, Furtado S, Pradeep R, Javali M, Acharya P, et al. Spectrum of neurological manifestations among acute COVID-19 and long COVID-19 &#x2013; A retrospective observational study. Romanian Journal of Neurology. 2022;21:176&#x2013;182. doi: 10.37897/RJN.2022.2.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.37897/RJN.2022.2.14</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh R, Grach SL, Ghosh AK, Bierle DM, Salonen BR, Collins NM, et al. The Female-Predominant Persistent Immune Dysregulation of the Post-COVID Syndrome. Mayo Clin Proc. 2022;97(3):454&#x2013;464. doi: 10.1016/j.mayocp.2021.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2021.11.033</ArticleId><ArticleId IdType="pmc">PMC8817110</ArticleId><ArticleId IdType="pubmed">35135695</ArticleId></ArticleIdList></Reference><Reference><Citation>Karosanidze I, Kiladze U, Kirtadze N, Giorgadze M, Amashukeli N, Parulava N, et al. Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial. Pharmaceuticals (Basel) 2022;15(3):834. doi: 10.3390/ph15030345.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15030345</ArticleId><ArticleId IdType="pmc">PMC8953947</ArticleId><ArticleId IdType="pubmed">35337143</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlefield KM, Watson RO, Schneider JM, Neff CP, Yamada E, Zhang M, et al. SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PLoS Pathog. 2022;18(5):e1010359. doi: 10.1371/journal.ppat.1010359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010359</ArticleId><ArticleId IdType="pmc">PMC9176759</ArticleId><ArticleId IdType="pubmed">35617421</ArticleId></ArticleIdList></Reference><Reference><Citation>Montefusco L, Ben Nasr M, D'Addio F, Loretelli C, Rossi A, Pastore I, et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021;3(6):774&#x2013;785. doi: 10.1038/s42255-021-00407-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-021-00407-6</ArticleId><ArticleId IdType="pmc">PMC9931026</ArticleId><ArticleId IdType="pubmed">34035524</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;224(11):1839&#x2013;1848. doi: 10.1093/infdis/jiab490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Naughton A, Kiersey R, Holden D, Gardiner M, et al. Longitudinal Analysis of COVID-19 Patients Shows Age-Associated T Cell Changes Independent of Ongoing Ill-Health. Front Immunol. 2021;12:678. doi: 10.3389/fimmu.2021.676932.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.676932</ArticleId><ArticleId IdType="pmc">PMC8138306</ArticleId><ArticleId IdType="pubmed">34025675</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyas C, Dalmacion D, Almeligy A, Juan R, Pernia-Cuberos JD, Obaid A, et al. Four distinct cases of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 Infection at a Community Hospital in New Jersey. Cureus. 2021;13(12):e20651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8783951</ArticleId><ArticleId IdType="pubmed">35103207</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler JB, Butuci M, Wong A, Kamboj AP, Youngblood BA. Mast cell activation is associated with post-acute COVID-19 syndrome. Allergy. 2022;77(4):1288&#x2013;1291. doi: 10.1111/all.15188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15188</ArticleId><ArticleId IdType="pmc">PMC9299596</ArticleId><ArticleId IdType="pubmed">34820848</ArticleId></ArticleIdList></Reference><Reference><Citation>Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: a systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1&#x2013;9. doi: 10.1002/rmv.2141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2141</ArticleId><ArticleId IdType="pmc">PMC7460877</ArticleId><ArticleId IdType="pubmed">32845568</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiu HH, Graham AL, Stengel RF. Dynamics of a cytokine storm. PLoS ONE. 2012;7(10):e45027. doi: 10.1371/journal.pone.0045027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0045027</ArticleId><ArticleId IdType="pmc">PMC3462188</ArticleId><ArticleId IdType="pubmed">23049677</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Shen J, Han Y, Qiao Q, Dai W, He B, et al. Upregulated IL-6 indicates a poor COVID-19 prognosis: a call for tocilizumab and convalescent plasma treatment. Front Immunol. 2021;12:598799. doi: 10.3389/fimmu.2021.598799.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.598799</ArticleId><ArticleId IdType="pmc">PMC7969719</ArticleId><ArticleId IdType="pubmed">33746945</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020;96:467&#x2013;474. doi: 10.1016/j.ijid.2020.05.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.05.055</ArticleId><ArticleId IdType="pmc">PMC7233226</ArticleId><ArticleId IdType="pubmed">32425643</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 2020;7(6):998&#x2013;1002. doi: 10.1093/nsr/nwaa041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nsr/nwaa041</ArticleId><ArticleId IdType="pmc">PMC7108005</ArticleId><ArticleId IdType="pubmed">34676125</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. Nat Rev Immunol. 2013;13(12):875&#x2013;887. doi: 10.1038/nri3547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3547</ArticleId><ArticleId IdType="pmc">PMC4096436</ArticleId><ArticleId IdType="pubmed">24157572</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>